Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal
- PMID: 16079072
- PMCID: PMC1280342
- DOI: 10.1289/ehp.7712
Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal
Abstract
Thimerosal is a preservative that has been used in manufacturing vaccines since the 1930s. Reports have indicated that infants can receive ethylmercury (in the form of thimerosal) at or above the U.S. Environmental Protection Agency guidelines for methylmercury exposure, depending on the exact vaccinations, schedule, and size of the infant. In this study we compared the systemic disposition and brain distribution of total and inorganic mercury in infant monkeys after thimerosal exposure with those exposed to MeHg. Monkeys were exposed to MeHg (via oral gavage) or vaccines containing thimerosal (via intramuscular injection) at birth and 1, 2, and 3 weeks of age. Total blood Hg levels were determined 2, 4, and 7 days after each exposure. Total and inorganic brain Hg levels were assessed 2, 4, 7, or 28 days after the last exposure. The initial and terminal half-life of Hg in blood after thimerosal exposure was 2.1 and 8.6 days, respectively, which are significantly shorter than the elimination half-life of Hg after MeHg exposure at 21.5 days. Brain concentrations of total Hg were significantly lower by approximately 3-fold for the thimerosal-exposed monkeys when compared with the MeHg infants, whereas the average brain-to-blood concentration ratio was slightly higher for the thimerosal-exposed monkeys (3.5 +/- 0.5 vs. 2.5 +/- 0.3). A higher percentage of the total Hg in the brain was in the form of inorganic Hg for the thimerosal-exposed monkeys (34% vs. 7%). The results indicate that MeHg is not a suitable reference for risk assessment from exposure to thimerosal-derived Hg. Knowledge of the toxicokinetics and developmental toxicity of thimerosal is needed to afford a meaningful assessment of the developmental effects of thimerosal-containing vaccines.
Figures







Similar articles
-
Identification and distribution of mercury species in rat tissues following administration of thimerosal or methylmercury.Arch Toxicol. 2010 Nov;84(11):891-6. doi: 10.1007/s00204-010-0538-4. Epub 2010 Apr 13. Arch Toxicol. 2010. PMID: 20386881
-
Toxicity of ethylmercury (and Thimerosal): a comparison with methylmercury.J Appl Toxicol. 2013 Aug;33(8):700-11. doi: 10.1002/jat.2855. Epub 2013 Feb 11. J Appl Toxicol. 2013. PMID: 23401210 Review.
-
Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine.Toxicol Sci. 2011 Apr;120(2):499-506. doi: 10.1093/toxsci/kfr009. Epub 2011 Jan 20. Toxicol Sci. 2011. PMID: 21252391
-
Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines.Pediatrics. 2008 Feb;121(2):e208-14. doi: 10.1542/peds.2006-3363. Pediatrics. 2008. PMID: 18245396
-
An assessment of thimerosal use in childhood vaccines.Pediatrics. 2001 May;107(5):1147-54. doi: 10.1542/peds.107.5.1147. Pediatrics. 2001. PMID: 11331700 Review.
Cited by
-
Molecular Fates of Organometallic Mercury in Human Brain.ACS Chem Neurosci. 2022 Jun 15;13(12):1756-1768. doi: 10.1021/acschemneuro.2c00166. Epub 2022 May 11. ACS Chem Neurosci. 2022. PMID: 35543423 Free PMC article.
-
Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines.Neurochem Res. 2011 Jun;36(6):927-38. doi: 10.1007/s11064-011-0427-0. Epub 2011 Feb 25. Neurochem Res. 2011. PMID: 21350943 Review.
-
Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System.Antioxid Redox Signal. 2017 Nov 1;27(13):989-1010. doi: 10.1089/ars.2016.6925. Epub 2017 May 18. Antioxid Redox Signal. 2017. PMID: 28443683 Free PMC article. Review.
-
Blood mercury concentrations in CHARGE Study children with and without autism.Environ Health Perspect. 2010 Jan;118(1):161-6. doi: 10.1289/ehp.0900736. Environ Health Perspect. 2010. PMID: 20056569 Free PMC article.
-
Thimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalink.N Am J Med Sci. 2014 Oct;6(10):519-31. doi: 10.4103/1947-2714.143284. N Am J Med Sci. 2014. PMID: 25489565 Free PMC article.
References
-
- American Academy of Pediatrics and U.S. Public Health Service. Thimerosal in vaccines: a joint statement. MMWR Morb Mortal Wkly Rep. 1999;48:563–565. - PubMed
-
- Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001;107:1147–1154. - PubMed
-
- Berlin M, Crawford A, Grant DVM, Hellstrom J, Schultz A. Neurotoxicity of methylmercury in squirrel monkeys. Arch Environ Health. 1975;30:340–348. - PubMed
-
- Biroscak BJ, Fiore AE, Fasano N, Fineis P, Collins MP, Stoltman G. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics. 2003;111:645–649. - PubMed
-
- Blaxill MF, Redwood L, Bernard S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med Hypotheses. 2004;62:788–794. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources